Last $1.15 USD
Change Today -0.01 / -0.86%
Volume 187.2K
CRDC On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 5:20 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

cardica inc (CRDC) Key Developments

Cardica Announces Data Presentation at Amazing Technologies Session of 14th Annual World Congress Of Endoscopic Surgery

Cardica Inc. announced that Dr. Stefanos Demertzis, associate professor at the University of Berne, Switzerland and senior staff cardiac surgeon and deputy head of the department of cardiac surgery at the Cardiocentro Ticino Lugano, completed a study that demonstrated that there was no difference in the chronic healing response between the innovative D-shaped staple design of the Cardica five-millimeter MicroCutter XCHANGE(R) 30 and the B-shaped staple design used in conventional 12-millimeter surgical staplers. The results of the study, entitled 'Beyond the 'B': A New Concept of the Surgical Staple Enabling Miniature Staplers,' were presented by Dr. Lee Swanstrom, chief innovations officer at the University of Strasbourg's University Hospitals Institutes, clinical professor of surgery for Oregon Health and Sciences University and medical director of Cardica, as part of the Amazing Technologies Session at the 14(th) Annual World Congress of Endoscopic Surgery in Paris, France, a meeting hosted by the European Association for Endoscopic Surgery (EAES) in conjunction with the SFCE (Societe Francaise de Chirurgie Endoscopique) and the International Society for Laparoscopic ColoRectal Surgery (ISLCRS). The study compared the standard B-form staple, used in conventional 12-millimeter surgical staplers, to the innovative D-shaped staple used in the Cardica MicroCutter XCHANGE 30, the world's first and only five-millimeter surgical stapler that articulates to 80 degrees. Chronic histology performed showed that the D-shaped staple elicited a normal healing response with minimal inflammation and lack of excessive scar tissue formation. Further, there was no difference in the chronic healing response between 'D' and 'B' shaped staples.

Cardica Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2014

Cardica Inc. reported earnings results for the third quarter and nine months ended March 31, 2014. Net loss for the third quarter ended March 31, 2014 was $4.38 million, or $0.09 loss per share, compared to a net loss of $3.95 million, or $0.1 loss per share, for the same quarter ended March 31, 2013. Total revenue for the third quarter ended March 31, 2014 was $934,000, compared to $868,000 for the same quarter ended March 31, 2013. Net loss for the nine months ended March 31, 2014 was $12.29 million, or $0.24 loss per share, compared to a net loss of $12.28 million, or $0.33 loss per share, for the same period ended March 31, 2013. Total revenue for the nine months ended March 31, 2014 was $2.59 million, compared to $2.63 million for the same period ended March 31, 2013.

Cardica Inc. Announces Unaudited Earnings Results for Third Quarter and Nine Months Ended Mar. 31, 2014

Cardica Inc. announced unaudited earnings results for third quarter and nine months ended Mar. 31, 2014. For the quarter, the company reported revenue of $934,000, loss from operations of $4,254,000, net loss of $4,379,000 or $0.09 basic and diluted per share compared to the revenue of $868,000, loss from operations of $3,836,000, net loss of $3,946,000 or $0.1 basic and diluted per share, for the same quarter a year ago. For the year to date, the company reported revenue of $2,590,000, loss from operations of $11,953,000, net loss of $12,290,000 or $0.24 basic and diluted per share compared to the revenue of $2,627,000, loss from operations of $11,950,000, net loss of $12,278,000 or $0.33 basic and diluted per share, for the same period a year ago.

Cardica Inc. to Report Q3, 2014 Results on May 01, 2014

Cardica Inc. announced that they will report Q3, 2014 results at 5:00 PM, Eastern Standard Time on May 01, 2014

Cardica Inc., Q3 2014 Earnings Call, May 01, 2014

Cardica Inc., Q3 2014 Earnings Call, May 01, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRDC:US $1.15 USD -0.01

CRDC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cytori Therapeutics Inc $2.21 USD -0.02
Pluristem Therapeutics Inc $2.93 USD 0.00
Stereotaxis Inc $3.32 USD +0.03
Uroplasty Inc $2.64 USD -0.03
Vision Sciences Inc/DE $1.20 USD +0.0101
View Industry Companies
 

Industry Analysis

CRDC

Industry Average

Valuation CRDC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDICA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.